UG»·Çò

ÄúÏÖÔÚµÄλÖãº ÍøÕ¾Ê×Ò³>´ÙÏúÖÐÐÄ

ÅÁ½ðÉ­²¡

2022-03-03 09:24

Åä¾°



ÅÁ½ðÉ­²¡£¡£¨Parkinson’s disease, PD£©ÊdzýÁËÕâ¸ö²¡Ö®Í⣬£¬£¬Ììϵڶþ´óµÄÉñ¾­ÍËÐÐÐÔ¼²²¡¡£¡£ÎªÁ˼ÍÄî·¢Ã÷ÕâÒ»¼²²¡µÄÓ¢¹úÒ½Éúղķ˹·ÅÁ½ðÉ­£¬£¬£¬ÈËÃǽ«ËûµÄÉúÈÕ——4ÔÂ11ÈÕÈ·¶¨Îª“ÌìÏÂÅÁ½ðÉ­ÈÕ”¡£¡£



ÅÁ½ðÉ­²¡µÄÖ÷ÒªÖ¢×´ÌåÏÖΪÔ˶¯Õϰ­£¬£¬£¬ÈçÔ˶¯»ºÂý£¨bradykinesia£©¡¢½©Ö±£¨rigidity£©¡¢¾²Ö¹ÐÔÕð²ü£¨tremor£©µÈ¡£¡£³ý´ËÖ®ÍâÅÁ½ðÉ­»¼ÕßÒ²ÌåÏÖ³öÁ˸ÐÊÜÕϰ­ºÍÈÏÖª¹¦Ð§Õϰ­µÈ·ÇÔ˶¯Ö¢×´¡£¡£Ò»Ïî2016ÄêµÄÑо¿ÏÔʾ£¬£¬£¬60ËêÒÔÉÏÍíÄêÈËȺÖÐÅÁ½ðÉ­²¡µÄ»¼²¡ÂÊԼΪ1%-2%£»£»£»£»£»£»¶øÔÚ80ËêÒÔÉÏÈËȺÖУ¬£¬£¬ÕâÒ»±ÈÀýÔò»áÉÏÉýÖÁ4%×óÓÒ1¡£¡£ÏÖÔÚ£¬£¬£¬ÎÒ¹úµÄÅÁ½ðÉ­»¼ÕßÒѾ­µÖ´ïÁË200ÍòÈË£¬£¬£¬Õ¼È«ÌìÏÂÅÁ½ðÉ­²¡È˵ÄÒ»°ë×óÓÒ¡£¡£ÔÚÎÒ¹úÀÏÁ仯Öð²½¼ÓÉîµÄÅä¾°Ï£¬£¬£¬ÅÁ½ðÉ­²¡ÒѾ­³ÉΪÍþвÍíÄêÈËȺÉíÐÄ¿µ½¡µÄÒ»´ó“ɱÊÖ”¡£¡£



ÅÁ½ðÉ­²¡×îΪͻ³öµÄ²¡Àí¸Ä±äÊÇÖÐÄÔºÚÖÊÖжà°Í°·ÄÜÉñ¾­ÔªµÄ±äÐÔºÍéæÃü¡£¡£ÁíÍâÈËÃÇ·¢Ã÷£¬£¬£¬Ê£ÓàÉñ¾­ÔªÖзÒ×СÌåµÄÐγɺÍα-Í»´¥ºËÂѰ׵ÄȺ¼¯Ò²ÊÇÅÁ½ðÉ­²¡µÄµä·¶ÌØÕ÷Ö®Ò»¡£¡£ÅÁ½ðÉ­²¡µÄ²¡ÒòÖÁ½ñδÃ÷£¬£¬£¬Ö¤¾ÝÏÔʾÒÅ´«¡¢ÇéÐÎÎÛȾ¡¢ÐàÂõµÈÒòËØ¾ùÔÚÅÁ½ðÉ­²¡µÄ±¬·¢ÖÐÊÎÑÝÁËÒ»¶¨µÄ½ÇÉ«¡£¡£



ΪÁËÑо¿ÅÁ½ðÉ­²¡µÄ·¢²¡Ôµ¹ÊÔ­ÓÉÒÔ¼°Ì½Ë÷еÄÁÙ´²µÄÖÎÁÆÊֶΣ¬£¬£¬ÖƱ¸ÓÐÓõÄÅÁ½ðÉ­²¡¶¯ÎïÄ£×ÓÓÐ×ÅÖ÷ÒªµÄÒâÒå¡£¡£ÔÚ±¾ÎÄÖÐÎÒÃǽ«ÏÈÈÝ3ÖÖÖ÷Á÷µÄÅÁ½ðÉ­²¡µÄ¶¯ÎïÄ£×ÓµÄÔ­ÀíºÍÖÆ±¸ÒªÁì¡£¡£¶øÔÚÏÂÆÚ£¬£¬£¬ÎÒÃǽ«ÏÈÈÝÄ¥Á·¾ÞϸÊóÅÁ½ðÉ­Ä£×ÓÔìģЧ¹ûµÄ²¡ÀíºÍÐÐΪѧҪÁì¡£¡£



1.MPTPÓÕµ¼Ð¡ÊóÅÁ½ðÉ­Ä£×Ó



1982Ä꣬£¬£¬7¸öÀ´×Ô¼ÓÀû¸£ÄáÑÇÖÝÊ¥¿ËÀ­À­ÏصēæÒƤʿ”ÔÚÎüʳÁËÒ»Öֺϳɺ󱻽ôÆÈËÍÍùÒ½Ôº¾ÈÖΡ£¡£Ò½Éú¾ªÑȵط¢Ã÷£¬£¬£¬Õâ7λ»¼ÕßËäÈ»ÄêËêÇáÇᣬ£¬£¬Ðж¯È´Ïñ°ÙËêÀÏÈËÒ»Ñù»ºÂý£¬£¬£¬²¢ÅãͬÓÐÖ«ÌåÕð²üµÄÕ÷Ï󣬣¬£¬ºÍÅÁ½ðÉ­²¡µÄÌåÏÖÊ®·ÖÏàËÆ¡£¡£½øÒ»²½µÄÄ¥Á·Åú×¢£¬£¬£¬ÕâÅúºÏ³ÉÖк¬ÓÐÒ»ÖÖÃûΪ1-¼×»ù-4-±½»ù-1,2,3,6-ËÄÇâßÁण¨1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP£©µÄÔÓÖÊ2¡£¡£1984Ä꣬£¬£¬Ë¹Ì¹¸£´óѧµÄÉñ¾­Ñ§¼ÒÍþÁ®·À¼Ë¹¶ÙÈ·ÈÏMPTPÕýÊǵ¼ÖÂÕâЩÄêÇáÈË·ºÆðÅÁ½ðÉ­ÑùÖ¢×´µÄ×ï¿ý×ï¿ý3¡£¡£



´ÓÔ­ÀíÀ´¿´£¬£¬£¬MPTP×Ô¼º¶Ôϸ°û²¢ÎÞÆÈº¦×÷Óᣡ£¿ÉÊǵ±MPTP½øÈëÌåÄں󣬣¬£¬ÓÉÓÚ×ÔÉíÓÅÒìµÄÖ¬ÈÜÐÔ£¬£¬£¬MPTP¿ÉÒÔÈÝÒ×´©¹ýѪÄÔÆÁÕÏ£¨blood-brain barrier, BBB£©½øÈëÖÐÊàÉñ¾­ÏµÍ³4¡£¡£¶øÔÚÄÔÖУ¬£¬£¬MPTP»á±»Éñ¾­½ºÖÊϸ°ûÖеĵ¥°·Ñõ»¯Ã¸B£¨MAO-B£©´úлΪһÖÖÃûΪMPDP +µÄÖÐÐÄÌå¡£¡£¶ø¸ÃÖÐÐÄÌåÔÙ¾­ÓɽøÒ»²½µÄÑõ»¯£¬£¬£¬×îÖÕÐγÉÓж¾µÄ´úлÎï¼×»ù-±½»ùËÄÇâßÁà¤æfÑΣ¨MPP +£©5¡£¡£



MPP+µÄ½á¹¹¿¿½ü¶à°Í°·£¬£¬£¬Òò´Ë»á¹ýʧµØ±»ÖÐÄÔ¶à°Í°·Éñ¾­ÔªÄ¤ÉϵĶà°Í°·×ªÔËÌ壨dopamine transporter, DAT£©Ñ¡ÔñÐÔÖØÎüÊÕ½øÈëϸ°ûÄÚ6¡£¡£¶øÒ»µ©½øÈëϸ°û£¬£¬£¬MPP+Ôò»á“Ð×Ïà±Ï¶”£¬£¬£¬Ëü»áÒÖÖÆÏßÁ£ÌåºôÎüÁ´¸´ºÏÌåIµÄ»îÐÔ7£¬£¬£¬´Ó¶ø×è¶Ïµç×Ó×ªÒÆÁ´£¬£¬£¬ïÔÌ­ATPµÄÌìÉú²¢Ôö½ø»îÐÔÑõ(reactive oxygen species, ROS)µÄ±¬·¢£¬£¬£¬×îÖÕÔì³ÉÉñ¾­ÔªµÄËðÉË8¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

ͼ1 MPTPµÄ´úл;¾¶ºÍMPP+ÔÚ°ûÄڵķ¾¶







ÕýÓÉÓÚMPTPÊǵÚÒ»¸öÒ²ÊÇÏÖÔÚÄܹ»ÔÚÈËÀàÉíÉϸ´ÏÖÅÁ½ðÉ­Ö¢×´µÄÉñ¾­¶¾ËØ£¨Ä³ÖÖÒâÒåÉÏ»¹ÒªÐ»Ð»Õ⼸λ¼ÓÖݵÄÄêÇáÈË£©£¬£¬£¬MPTPÓÕµ¼µÄÅÁ½ðÉ­Ä£×Ó³ÉΪÁËÔÚģʽ¶¯ÎïÉÏÑо¿ÅÁ½ðÉ­²¡ÁÙ´²ÁÆ·¨µÄ“½ð±ê×¼”£¬£¬£¬ÓÈÆäÊÇMPTPÓÕµ¼µÄ·ÇÈËÁ鳤ÀࣨÈçºãºÓºï£©ÅÁ½ðÉ­Ä£×Ó¡£¡£¶øMPTPÓÕµ¼µÄСÊóÅÁ½ðÉ­Ä£×ÓÓÉÓÚÔìÄ£ÊÖÒÕÏà¶Ô¼òÆÓ£¨Ö»ÐèÒª¸¹Ç»×¢É䣩¡¢¶Ô¶à°Í°·Éñ¾­ÔªµÄɱÉËЧ¹ûÎȹÌÒ²»ñµÃÁËÆÕ±éµÄÈϿɡ£¡£²»ÉÙ¹ØÓÚ¶à°Í°·ÄÜÉñ¾­ÔªéæÃü»úÖÆ·½ÃæµÄÑо¿¶¼½ÓÄÉMPTPÓÕµ¼µÄСÊóÅÁ½ðÉ­Ä£×Ó×÷ΪʵÑ鷶ʽ¡£¡£

¶¯ÎÐÛÐÔC57BL/6£¬£¬£¬Ô¼Äª7-8ÖÜÁ䣬£¬£¬ÌåÖØ25-30 g¡£¡£×¢ÖØMPTPÓÕµ¼µÄСÊóÅÁ½ðÉ­Ä£×Ó¶Ô¶¯ÎïµÄÐÔ±ð¡¢ÌåÖØ¡¢ÄêËêÉõÖÁƷϵȪԴ£¨ÊÇJackson labÕÕ¾ÉCharles River£©¾ùºÜÊÇÃô¸Ð¡£¡£ÔÚÌôÑ¡¶¯ÎïµÄʱ¼äҪʮ·ÖСÐÄ¡£¡£

ËÇÑø£º¶©¹ºµÄ¶¯Îﵽλºó£¬£¬£¬ÔÚ×¢ÉäǰÎñ±ØË³Ó¦ÐÔËÇÑø1ÖÜ×óÓÒ¡£¡£ÓÉÓÚ³¤¾àÀëÔËÊä»á¸Ä±äÄÔµÄ״̬£¬£¬£¬Òò´ËÐèÒª5-7Ììʱ¼äÀ´Ê¹¶¯Îï»Ö¸´²¢Ë³Ó¦ÇéÐΡ£¡£

×¢É䣺ÔÚ×¢Éäµ±ÌìÅäÖÆºÃÐÂÏʵÄMPTPÈÜÒº£¬£¬£¬È»ºóÿֻ¶¯Îï°´14-20 mg/kgÌåÖØµÄ¼ÁÁ¿¸¹Ç»×¢ÉäMPTP¡£¡£¾àÀë2Сʱºó¾ÙÐÐÏÂÒ»´Î×¢É䣬£¬£¬µ±Ìì¹²¾ÙÐÐ4´Î×¢Éä¡£¡£

ÊõºóÕչ˻¤Ê¿£º×¢ÉäÖ®ºóԼĪ30·ÖÖÓ£¬£¬£¬Ð¡Êó¾Í»á·ºÆðÀàËÆÅÁ½ðÉ­µÄÖ¢×´£¬£¬£¬Èçǿֱ»òÕð²üµÈ¡£¡£¶øÔÚԼĪ3Сʱºóδ±»´úлµÄMPTP½«»áËæ×Ŷ¯ÎïµÄÉøÍ¸Îï±»Êͷŵ½µæÁÏÖС£¡£Òò´ËÔÚ×¢ÉäÖ®ºóСÊóÐèÒª¾ÙÐÐÑÏ¿áµÄ¸ôÀëËÇÑø¡£¡£ÆäʹÓõĵæÁÏ¡¢ÒûË®±ØÐè¾­ÓÉÎÞº¦»¯´¦Öóͷ££¬£¬£¬È»ºó×÷ΪҽÁÆÀ¬»ø·ÅÆú¡£¡£Ô¼Äª3-4Öܺó¿ÉÒÔ¶Ô¶¯ÎïµÄ²¡ÀíºÍÐÐΪÌåÏÖ¾ÙÐмì²â¡£¡£



2.6-OHDAÓÕµ¼ÅÁ½ðÉ­Ä£×Ó



6-ôǶà°Í°·£¨6-hydroxydopamine, 6-OHDA£©ÊǶà°Í°·µÄôÇ»ù»¯ÑÜÉúÎ£¬£¬ÓÚ1959ÄêÊ×Ïȱ»SenohµÈÈËÀÖ³ÉÊèÉ¢9¡£¡£×Ô¾õÏÖÒÔÀ´µÄ°ë¸ö¶àÊÀ¼ÍÖУ¬£¬£¬6-OHDAÒ»Ö±ÔÚÅÁ½ðÉ­²¡µÄÁÙ´²Ç°Ñо¿ÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«¡£¡£ÓÉUngerstedtºÍArbuthnottÔÚ1970ÄêÅäºÏ½¨ÉèµÄµ¥²à×¢ÉäÐýתģ×Ó³ÉΪÁËÔÚģʽ¶¯ÎïÉϱ»×îΪÆÕ±éʹÓõÄÅÁ½ðÉ­Ä£×ÓÖ®Ò»10¡£¡£

6-OHDA¶ÔÉñ¾­ÔªµÄÆÈº¦×÷ÓÃÓÐÒ»¸ö“Á½²½×ß”µÄÀú³Ì¡£¡£µÚÒ»²½ÊÇÌØÒìÐÔµØÔÚ¶à°Í°·ÄÜÉñ¾­ÔªÄڵĻýÀÛ¡£¡£ÓÉÓÚ6-OHDAµÄ½á¹¹ºÍ¶ù²è·Ó°·ÀàËÆ£¬£¬£¬Òò´ËÊÍ·ÅÔÚϸ°û¼äÖÊÖеÄ6-OHDA»á±»¶à°Í°·Éñ¾­Ôª°ûÌå»òÍ»ÆðÉϵĶà°Í°·×ªÔËÌå¹ýʧµØÊ¶±ð²¢ÖØÎüÊÕ½øÈëϸ°û£¨Í¼2£©¡£¡£µÚ¶þ²½ÔòÊÇϸ°û¶¾ÐÔ¡£¡£µ±6-OHDA½ø×ÅÃÔ¾­Ôªºó£¬£¬£¬Ò»·½Ã潫»á±»µ¥°·Ñõ»¯Ã¸-A£¨MAO-A£©´ß»¯ÐγɹýÑõ»¯Ç⣨H2O2£©¡£¡£¹ýÑõ»¯Çâ×Ô¼º¾ßÓкÜÇ¿µÄϸ°û¶¾ÐÔ£¬£¬£¬Í¬Ê±Ò²»á´¥·¢Ñõ×ÔÓÉ»ùµÄÐγÉ12¡£¡£¶øÁíÒ»·½Ã棬£¬£¬×Ô¶¯Ñõ»¯£¨autooxidation£©×÷ÓÃËù´ó×Ú±¬·¢µÄ»îÐÔÑõºÍõ«Àà²úÆ·Áè¼ÝÁËϸ°ûÄÚ¿¹Ñõ»¯Ã¸µÄÔâÊÜÄÜÁ¦£¬£¬£¬µ¼ÖÂϸ°û½á¹¹ºÍ´úлµÄÔÓÂÒ£¬£¬£¬×îÖÕЧ¹û¾ÍÊÇÉñ¾­ÔªµÄËðÉË£¨Í¼2£©¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ2  6-OHDA½éµ¼µÄÉñ¾­¶¾ÐÔ×÷ÓûúÖÆ



ÓëMPTP²î±ðµÄÊÇ£¬£¬£¬6-OHDA²¢²»¿É´©Í¸ÑªÄÔÆÁÕÏ¡£¡£Òò´ËΪÁ˵ִïÖÐÊàÉñ¾­ÏµÍ³»ÙÉ˵ÄЧ¹û£¬£¬£¬ÔÚʹÓÃ6-OHDA¾ÙÐÐÅÁ½ðÉ­ÔìģʱÐèҪʹÓÃÄÔÁ¢Ì嶨λעÉäÊÖÒÕ½«6-OHDA×¢Èëµ½ºÚÖÊ-ÎÆ×´Ì壨striatonigral£©ÕâÒ»¶à°Í°·ÄÜͶÉäͨ·ÖС£¡£ÏêϸµÄ×¢Éäλµã¿ÉÒÔÊǺÚÖÊÖÂÃܲ¿£¨substantia nigra pars compacta, SNpc£©¡¢ÎÆ×´Ì壨striatum£©»òÕßλÓÚ¶þÕßÖ®¼äµÄǰÄÔÄÚ²àÊø£¨MFB£©¡£¡£



¶¯Î6-8ÖÜÁäµÄC57/BLСÊ󣬣¬£¬êòĵ²»ÏÞ£¬£¬£¬ÌåÖØ20-25 g×óÓÒ¡£¡£

ËÇÑø£ºÓëMPTPÓÕµ¼µÄÄ£×ÓÏàͬ£¬£¬£¬¶¯Îï¶©¹ºÖ®ºóÐèÒªÖÁÉÙ˳ӦÐÔËÇÑø1ÖܺóÔÙ¾ÙÐÐÔìÄ£ÊÖÊõ¡£¡£

ÄÔ¶¨Î»×¢É䣺ÔÚ33GµÄHamilton×¢ÉäÆ÷»ò²£Á§µç¼«ÖÐÔ¤ÏÈÎüÈë1 μL×óÓÒŨ¶ÈΪ3 μg/mLµÄ6-OHDAÈÜÒº¡£¡£Ð¡ÊóÂé×íºóÀο¿ÔÚÄÔÁ¢Ì嶨λÒÇÉÏ¡£¡£¼ô¿ªÍ·Æ¤ºóÓÃÃÞÇ©ÇáÇá²ÁÊí¹ÇÍâò½«Ç°Ø¶£¨bregma£©ºÍºóض£¨lambda£©µã̻¶³öÀ´¡£¡£µ÷ÀíÁ¢Ì嶨λÒÇ£¬£¬£¬½«Ç°Ø¶ºÍºóضµãµÄ¸ß¶Èµ÷Àíµ½Ò»Ö´ӶøÊ¹Â­¹Ç¼á³Öˮƽ¡£¡£ÒÔbregmaµãΪԭµã£¬£¬£¬ÕÒµ½×¢ÉäλµãËùÔÚµÄ×ø±ê£¬£¬£¬ÓÃÑÀ¿Æ×꽫עÉäλµãÉÏ·½µÄ­¹Ç×꿪һ¸öС¶´¡£¡£ÔÚ6-OHDAÓÕµ¼µÄÄ£×ÓÖУ¬£¬£¬×¢Éäλµã¿ÉÒÔÊǺÚÖÊ£¨AP -2.90 mm; ML +1.10 mm; DV -4.50 mm£©£¬£¬£¬Ò²¿ÉÒÔÊÇǰÄÔÄÚ²àÊø£¨AP -1.20 mm; ML +1.10 mm; DV -5.00 mm£©»òÎÆ×´Ì壨AP +0.2 mm; ML ±2.00 mm; DV -2.60 mm£©¡£¡£½«²£Á§µç¼«»ò×¢ÉäÕ뻺Âý²åÈë×¢Éäλµã£¬£¬£¬ÒÔ0.2 μL/minµÄËÙÂʽ«6-OHDA×¢É䵽ĿµÄÄÔÇø¡£¡£×¢É俢ʺ󣬣¬£¬×¢ÉäÕëÓ¦¸Ã¼ÌÐøÍ£ÁôÔÚ×¢Éäλµã5·ÖÖÓ×óÓÒÒÔʹҩÎïÄܹ»³ä·ÖÀ©É¢¡£¡£ÌáÆð×¢ÉäÕ룬£¬£¬½«¶¯ÎïµÄͷƤ·ìºÏ²¢Ïû¶¾¡£¡£

ÊõºóÕչ˻¤Ê¿£ºÄÔ¶¨Î»×¢ÉäÍê³Éºó½«¶¯Îï·ÅÔÚ¼ÓÈȰå»òµÆ¹âÏÂÕÕÉä¼á³ÖÌåΡ£¡£´ý¶¯ÎïËÕÐѺó·Å»ØÁýÖС£¡£Êõºó3ÌìÄÚÌìÌ츹ǻעÉäÒ»´Î¿¹ÉúËØ¡£¡£Ô¼Äª3-4Öܺó¿ÉÒÔ¾ÙÐÐÐÐΪѧ¼ì²â¡£¡£












3.»ùÓÚα-Í»´¥ºËÂѰ׵ÄÄ£×Ó

³ýÁ˶à°Í°·Éñ¾­ÔªÉ¥Ê§Ö®Í⣬£¬£¬ÅÁ½ðÉ­²¡µÄÁíÒ»Öֵ䷶µÄÉñ¾­²¡Àí±ê¼ÇÊÇÊ£ÓàµÄÉñ¾­Ôª°ûÖÊÄÚ·ºÆðÒ»ÖÖÊÈËáÐÔµÄÈÝÄÉÌ壬£¬£¬¼´Â·Ò×СÌ壨Lewy bodies, LBs£©¡£¡£ÏÔ΢¾µÏ·ºÆðÔ²ÐεķۺìÉ«¾ùÖʽṹ¡£¡£Â·Ò×СÌåµÄÖ÷Òª×é³ÉÒòËØÊÇÒ»ÖÖ½Ð×öα-Í»´¥ºËÂѰף¨α-synuclein, α-Syn£©µÄÍ»´¥Ç°ÂѰס£¡£´ó×ÚÖ¤¾ÝÏÔʾ£¬£¬£¬α-Í»´¥ºËÂѰ׵ÄȺ¼¯ºÍ·Ò×СÌåµÄÐγÉÓë¶à°Í°·Éñ¾­ÔªµÄéæÃüÓÐ×ÅÇ×½üµÄÁªÏµ13¡£¡£

α-Í»´¥ºËÂѰ×ÓÉSNCA»ùÒò±àÂ룬£¬£¬ÊÇÒ»ÖÖÖ÷Òª±í´ïÔÚÍ»´¥Ç°ºÍºËÖܵĿÉÈÜÐÔÂѰס£¡£α-Í»´¥ºËÂѰ׼òÖ±Çй¦Ð§ÖÁ½ñÈÔ²»ÇåÎú£¬£¬£¬²»¹ýÓÐÖ¤¾ÝÏÔʾ¿ÉÄÜÓëÍ»´¥¿ÉËÜÐÔ»òÉñ¾­µÝÖÊÊÍ·ÅÏà¹Ø¡£¡£Õý³£×´Ì¬ÏµÄα-Í»´¥ºËÂѰ×ÒÔµ¥Ì壨monomers£©»òÕßαÂÝÐý×´£¨α-helical£©ÕÛµþµÄËľÛÌåÐÎʽ±£´æ£¬£¬£¬¿ÉÈܲ¢ÇÒÏÊÓÐȺ¼¯µÄÇéÐΣ»£»£»£»£»£»µ«ÔÚ²¡Àí״̬Ï£¬£¬£¬α-Í»´¥ºËÂѰ׻á¸Ä±ä¹¹ÏóΪ¸»º¬βƬ״£¨β-sheet£©ÕÛµþµÄ½á¹¹¡£¡£¹ýʧÕÛµþµÄα-Í»´¥ºËÂѰ׻áȺ¼¯ÆðÀ´ÐγɹѾÛÌ壬£¬£¬²¢Öð½¥ÏòÏËάԭºÍ²»ÈÜÐÔÏËάµÄÐÎ̬Éú³¤£¬£¬£¬×îÖÕ³Á»ýÔÚ·Ò×СÌåÖС£¡£³ý´ËÖ®Í⣬£¬£¬´ó×ÚÑо¿Ö¤¾ÝÅú×¢£¬£¬£¬¹ýʧÕÛµþµÄα-Í»´¥ºËÂѰ׿ÉÒÔÌåÏÖ³öëò¡¶¾£¨prion£©µÄÐÔ×Ó£¬£¬£¬ÓÕ·¢ÄÚÔ´α-Í»´¥ºËÂѰ׵ĹýʧÕÛµþºÍȺ¼¯£¬£¬£¬²¢Í¨Ï꾡°û¼äת´ïµÄ·½·¨ÔÚÉñ¾­ÔªÖ®¼äÀ©É¢¡£¡£

Ïà±ÈÓÚʹÓÃÉñ¾­¶¾ËØÉ±É˶à°Í°·Éñ¾­ÔªµÄÅÁ½ðÉ­Ä£×Ó£¬£¬£¬»ùÓÚα-Í»´¥ºËÂѰ׵ÄÅÁ½ðÉ­²¡Ä£×ÓÓÉÓÚÔÚʱ³ÌÉÏÄܹ»½ÏºÃµØÄ£ÄâÅÁ½ðÉ­²¡±¬·¢¡¢Éú³¤µÄÈ«Àú³Ì£¬£¬£¬ÕâÓÐÀûÓÚ·¢Ã÷ºÍʶ±ðеÄÖÎÁưе㡣¡£ÔÚÖî¶à»ùÓÚα-Í»´¥ºËÂѰ׵ÄÅÁ½ðÉ­Ä£×ÓÖУ¬£¬£¬½üÄêÀ´±»×îÆÕ±éʹÓõÄÄ£×Ó¿ÉÒÔ¹éÄÉΪ2ÖÖ£ºÔ¤ÖÆÏËά£¨pre-performed fibrils, PFFs£©ºÍAAV²¡¶¾¿ÅÁ£Ä£×Ó¡£¡£

ʹÓÃα-Í»´¥ºËÂѰ׵ÄÔ¤ÖÆÏËά¾ÙÐÐÔìÄ£Ê×ÏÈÐèÒªÖÆ±¸PFFs¡£¡£¼ò¶øÑÔÖ®£¬£¬£¬Ô¤ÖÆÏËάÊ×ÏÈÔÚÌåÍâÓÉÖØ×éµÄα-Í»´¥ºËÂѰ׵¥ÌåÌìÉú¡£¡£½ÓÏÂÀ´£¬£¬£¬Èº¼¯³ÉÔ­ÏËάµÄα-Í»´¥ºËÂѰױ»ÌáÈ¡³öÀ´²¢³¬ÉùÆÆËéΪ¶ÌÏËάµÄÐÎʽ14¡£¡£Ê¹ÓÃÄÔÁ¢Ì嶨λעÉäµÄ·½·¨½«PFFs×¢Éä½øÄÔÄÚ£¬£¬£¬ÔÚԼĪ12Öܺ󽫻áÓÕ·¢ÄÚÔ´α-Í»´¥ºËÂѰ׵ÄȺ¼¯¡¢Á×ËữºÍ·ºËØ»¯·´Ó¦¡£¡£

ÁíÒ»ÖÖÓÐÓõķ½·¨ÊÇʹÓÃÖØ×éÏÙÏà¹Ø²¡¶¾£¨recombinant adeno-associated virus, rAAV£©ÍâÔ´¹ý±í´ïÒ°ÉúÐÍ»òµãÍ»±äÐÍ£¨ÈçA53T£©α-Í»´¥ºËÂѰס£¡£ÖµµÃ×¢ÖØµÄµÄÊÇ£¬£¬£¬¹¹½¨AAVÔØÌå½ÓÄɵÄѪÇåÐÍºÍÆô¶¯×Ó£¬£¬£¬ÒÔ¼°²¡¶¾×¢ÉäµÄµÎ¶ÈºÍ¼ÁÁ¿¶¼»á¶Ôα-Í»´¥ºËÂѰ׹ý±í´ïµÄЧÂʱ¬·¢Ó°Ïì15¡£¡£ÏÖÔÚµÄÑо¿ÏÔʾ£¬£¬£¬Ê¹Óó£ÓõÄCMV»òÕßhSynÆô¶¯×Ó¾ù¿ÉÒÔÌṩ¸ßˮƽµÄ»ùÒò±í´ïЧÂÊ¡£¡£ÁíÍ⣬£¬£¬Ê¹ÓÃһЩת¼ºóµ÷¿ØÔª¼þ£¬£¬£¬ÈçÍÁ²¦Êó¸ÎÑײ¡¶¾×ªÂ¼ºóµ÷ÀíÐòÁУ¨WPRE£©»òÕßpoly(A)β°ÍͬÑù¿ÉÒÔÏÔÖøÌá¸ßת»ùÒòµÄЧÂÊ¡£¡£

¶¯Î6-8ÖÜÁäµÄC57/BLСÊó»òPDÏà¹ØµÄת»ùÒòÊ󣬣¬£¬êòĵ²»ÏÞ£¬£¬£¬ÌåÖØ20-25 g×óÓÒ¡£¡£

ËÇÑø£º¶¯Îï¶©¹ºÖ®ºóÐèÒªÖÁÉÙ˳ӦÐÔËÇÑø1ÖܺóÔÙ¾ÙÐÐÄÔ¶¨Î»×¢Éä¡£¡£

ÄÔ¶¨Î»×¢É䣺ʹÓÃ10 μL£¬£¬£¬33GµÄHamilton×¢ÉäÆ÷Ô¤ÏÈÎüÈë2.5 μL×óÓÒα-Í»´¥ºËÂѰ×PFFs£¬£¬£¬ÆäÖÐα-Í»´¥ºËÂѰ×ÏËάµÄº¬Á¿Ô¼Îª5 μg¡£¡£¶¯Î↑­ºÍµ÷ƽ²Ù×÷ÓÚ6-OHDA×¢ÉäÒ»Ö¡£¡£α-Í»´¥ºËÂѰ×ͨ³£±»µ¥²à×¢ÉäÔÚÎÆ×´Ì壨AP +0.2 mm; ML ±2.00 mm; DV -2.60 mm£©¡£¡£×¢ÉäÕ뻺Âý²åÈë×¢Éäλµã£¬£¬£¬ÒÔ0.1 μL/minµÄËÙÂʽ«PFFs×¢É䵽ĿµÄÄÔÇø¡£¡£×¢É俢ʺ󣬣¬£¬×¢ÉäÕëÓ¦¸Ã¼ÌÐøÍ£ÁôÔÚ×¢Éäλµã5·ÖÖÓ×óÓÒÒÔʹÏËά³ä·ÖÀ©É¢¡£¡£×îºóÌáÆð×¢ÉäÕ룬£¬£¬½«¶¯ÎïµÄͷƤ·ìºÏ²¢Ïû¶¾¡£¡£

ÈôÊÇÊDz¡¶¾×¢É䣬£¬£¬Ôò¹¹½¨AAV2/1-A53T(ÈËÀàα-Í»´¥ºËÂѰ×A53TµãÍ»±äÐÍ)-EGFP-WPRE²¡¶¾ÔØÌ壬£¬£¬ÓÃ×¢ÉäÆ÷»ò²£Á§µç¼«ÎüÊÕ1.5 μL£¬£¬£¬µÎ¶ÈΪ2-3×1012 v.g./mL²¡¶¾£¬£¬£¬²¢ÒÔ0.1 μL/minµÄËÙÂʵ¥²à×¢ÉäÔÚºÚÖÊ£¨AP -3.1 mm; ML -1.4 mm; DV -4.4 mm£©¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ3  ÎÆ×´Ìå×¢ÉäµÄ×ø±êʾÒâͼ

ÊõºóÕչ˻¤Ê¿£ºÄÔ¶¨Î»×¢ÉäÍê³Éºó½«¶¯Îï·ÅÔÚ¼ÓÈȰå»òµÆ¹âÏÂÕÕÉä¼á³ÖÌåΡ£¡£´ý¶¯ÎïËÕÐѺó·Å»ØÁýÖС£¡£Êõºó3ÌìÄÚÌìÌ츹ǻעÉäÒ»´Î¿¹ÉúËØ¡£¡£Ô¼Äª90Ììºó¶¯Îï»áÖð½¥ÌåÏÖ³öÅÁ½ðÉ­±íÐÍ¡£¡£

Copyright ? UG»·Çò    µØµã£ºÉϺ£ÊÐÆÖ¶«ÐÂÇø¹ú¼ÊÒ½Ñ§Ô°Çø×ÏÆ¼Â·908Ū19ºÅÂ¥

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

µã»÷ѯ¼Û

¡¾ÍøÕ¾µØÍ¼¡¿